Sugi Predict

Sugi Predict / Compounds / SCHEMBL6733274

SCHEMBL6733274

SCHEMBL6733274

Cc1ccc(-c2[nH]c(C(F)F)nc2-c2cc(F)c(S(C)(=O)=O)c(F)c2)cc1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 9/20 0.39
▸ PTGS1 P23219 6/20 0.36
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TGFBR1 P36897 2/20 0.34
▸ MAPK14 Q16539 4/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ ALOX5 P09917 2/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CSNK1D P48730 1/20 0.33
▸ CSNK1E P49674 1/20 0.33
▸ MAPK11 Q15759 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CSNK1A1L Q8N752 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6729768 0.94 PTGS2 (0.37) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6739524 0.93 MAPK14 (0.40) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6732448 0.90 PTGS2 (0.42) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6734450 0.90 PTGS1 (0.34) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6734141 0.90 PTGS2 (0.42) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6732575 0.90 PTGS1 (0.34) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6731818 0.90 PTGS2 (0.38) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6733298 0.88 ALDH1A1 (0.43) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6741134 0.88 KIF11 (0.36) PTGS2PTGS1ALDH1A1KDM4ELMNA
SCHEMBL6734272 0.88 KIF11 (0.39) PTGS2PTGS1ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 — — US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 — — US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 — — US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 — — US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.